PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCamrelizumab
Camrelizumab
Camrelizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target programmed cell death protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
577 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277C80.01710629131166
Hepatocellular carcinomaD006528C22.010461513191
Lung neoplasmsD008175C34.9072781848
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.063892772
Stomach neoplasmsD013274EFO_0003897C166384649
Squamous cell carcinomaD0022946404349
Non-small-cell lung carcinomaD0022895309647
Breast neoplasmsD001943EFO_0003869C5073410147
Esophageal squamous cell carcinomaD0000772776273335
Esophageal neoplasmsD004938C153237535
NeoplasmsD009369C8011214334
Triple negative breast neoplasmsD0647265239133
Nasopharyngeal carcinomaD0000772741181230
Show 29 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179615420
CholangiocarcinomaD018281C22.19211
Biliary tract neoplasmsD001661C24.921010
Neoplasm metastasisD009362EFO_000970819110
SarcomaD0125091910
OsteosarcomaD0125161426
Gastrointestinal neoplasmsD005770C26.9246
Renal cell carcinomaD002292EFO_0000376426
T-cell lymphomaD0163992415
T-cell lymphoma peripheralD0164112415
Show 67 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mouth neoplasmsD009062EFO_0003868C06.911
Hematologic neoplasmsD01933711
Hyperbaric oxygenationD00693111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K7722
ThrombosisD01392722
Catheter ablationD01711522
StentsD01560711
Venous thrombosisD020246I82.4011
Clear cell adenocarcinomaD01826211
AdenomyoepitheliomaD05533111
Acute kidney injuryD058186N1711
Male breast neoplasmsD01856711
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCamrelizumab
INNcamrelizumab
Description
Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB7CU5
CAS-ID
RxCUI
ChEMBL IDCHEMBL4297715
ChEBI ID
PubChem CID
DrugBank
UNII ID73096E137E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,678 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
366 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use